Key result
Inhaled MAP0004 causes smaller acute pulmonary arterial systolic pressure increases than intravenous dihydroergotamine.
Why the study?
Assessing the acute systemic cardiovascular effects of inhaled dihydroergotamine compared with intravenous administration was important due to potential differences in exposure and safety.
Does orally inhaled dihydroergotamine (MAP0004) prevent clinically significant acute increases in pulmonary arterial systolic pressure compared to intravenous dihydroergotamine in healthy adults?
RCT (n=24)
Double-blind
Randomized in random order for a 3-period crossover (2:1 ratio of females:males)
Does orally inhaled dihydroergotamine (MAP0004) prevent clinically significant acute increases in pulmonary arterial systolic pressure compared to intravenous dihydroergotamine in healthy adults?
Orally inhaled dihydroergotamine demonstrates a favorable cardiovascular safety profile, lacking the acute vasoactive increases in pulmonary arterial pressure seen with the intravenous formulation.
Answers are grounded in this paper and cite their sources.
Supports preferring orally inhaled over IV dihydroergotamine to limit acute pulmonary pressure rises; confirms placebo-like CV safety in this RCT.
OBJECTIVE: MAP0004 is an investigational product which delivers dihydroergotamine (DHE) through the lung via a breath-synchronized metered dose inhaler. The objective of this study was to compare the acute effects of orally inhaled and intravenous (IV) DHE to placebo on maximum change and area under the curve for pulmonary arterial systolic pressure (PASP). RESEARCH DESIGN AND METHODS: A randomized, double-blind, placebo-controlled, 3-period, crossover study of 24 health adults. Trial registration NCT01089062. Study assessments included pharmacokinetics, electrocardiograms (ECG), and validated echocardiographic (Doppler)-derived measures of PASP by echocardiogram. The primary endpoint was the absolute change in calculated PASP using area under the curve, 0 to 2 hours (AUC(0-2h)). RESULTS: The change in PASP with IV DHE was significantly different than MAP0004 and placebo (AUC(0-2h)2857, 2624, and 2453 mmHg*min, respectively). After a second dose of MAP0004, AUC(0-4h) remained lower with MAP0004 than with a single dose of IV DHE. Adverse events were more common with IV DHE than with MAP0004 or placebo. None of the treatments produced clinically significant changes in PASP or other cardiac parameters. Changes in PASP were significantly smaller with MAP0004 compared with IV DHE. CONCLUSION: These results indicate the effects 1 mg of orally inhaled DHE on the cardiovascular system are less than with 1 mg of IV DHE, and that serial echocardiography can be a useful noninvasive means of assessing acute systemic effects.
No takes yet. Share an insight, caveat, or question.
Kellerman et al. (2013) conducted an RCT in Healthy (n=24). MAP0004 (dihydroergotamine) vs. Placebo and intravenous (IV) dihydroergotamine 1 mg was evaluated on Absolute change in calculated pulmonary arterial systolic pressure (PASP) using area under the curve, 0 to 2 hours (AUC(0-2h)) (p=0.194). Orally inhaled MAP0004 produced significantly smaller acute changes in pulmonary arterial systolic pressure compared with intravenous dihydroergotamine, with cardiovascular effects comparable to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: